Settlement Agreement, Presentation of Trial Results, and Stock Price Update - Research Report on Johnson & Johnson, Mettler

Settlement Agreement, Presentation of Trial Results, and Stock Price Update -
   Research Report on Johnson & Johnson, Mettler-Toledo, Galena Biopharma,
                            Dendreon, and Amedisys

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 25, 2013

NEW YORK, November 25, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Mettler-Toledo International, Inc. (NYSE: MTD), Galena
Biopharma, Inc. (NASDAQ: GALE), Dendreon Corp. (NASDAQ: DNDN), and Amedisys
Inc. (NASDAQ: AMED). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Johnson & Johnson Research Report

On November 19, 2013, Johnson & Johnson reported that DePuy Orthopaedics, Inc.
(DePuy), a part of its DePuy Synthes Companies, and the Court-appointed
committee of lawyers representing ASR™ Hip System plaintiffs has entered into
a settlement agreement to compensate eligible ASR patients in the United
States who underwent surgery to replace their ASR hip, as of August 31, 2013.
Andrew Ekdahl, Worldwide President, DePuy Synthes Joint Reconstruction,
commented, "We are committed to the well-being of ASR patients, as
demonstrated by the voluntary recall and the program providing support for
recall-related care. The U.S. settlement program provides compensation for
eligible patients without the delay and uncertainty of protracted litigation.
DePuy remains committed to our purpose of advancing innovative treatment
options to serve those who need joint replacement surgery." The Full Research
Report on Johnson & Johnson - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/07a8_JNJ

--

Mettler-Toledo International, Inc. Research Report

On November 20, 2013, Mettler-Toledo International, Inc.'s (Mettler-Toledo)
stock increased 0.02%, ending the day's session at $248.40. Over the previous
three trading sessions, shares of Mettler-Toledo increased 0.37%, compared to
the Dow Jones Industrial Average Index, which increased 0.38% during the same
period. The Full Research Report on Mettler-Toledo International, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/ac69_MTD

--

Galena Biopharma, Inc. Research Report

On November 11, 2013, Galena Biopharma, Inc. (Galena Biopharma) announced a
poster presentation at the Society for Immunotherapy of Cancer (SITC)
Conference 2013 from November 7-10, 2013, in National Harbor, Maryland.
According to the Company, the data presented are the results of the Phase 1
portion of the trial for the Folate Binding Protein (FBP) vaccine. Mark J.
Ahn, President and CEO of Galena Biopharma, commented, "We are encouraged by
the initial results of our Phase 1 trial with the FBP vaccine, showing that it
is well-tolerated and demonstrated promising immune responses in high risk
gynecological cancers. As a result, we are moving forward with the Phase 2a
component which will be initiated by year end and will include the enrollment
of additional patients at the optimal dose as well implementing a booster
regimen." The Full Research Report on Galena Biopharma, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/cad6_GALE

--

Dendreon Corp. Research Report

On November 20, 2013, Dendreon Corp.'s (Dendreon) stock declined 4.07%, ending
the day's session at $2.83. Over the previous three trading sessions, shares
of Dendreon increased 11.42%, compared to the Nasdaq Composite Index, which
declined 1.62% during the same period. The Full Research Report on Dendreon
Corp. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/de0c_DNDN

--

Amedisys Inc. Research Report

On November 20, 2013, Amedisys Inc.'s (Amedisys) stock declined 1.79%, ending
the day's session at $14.30. Over the previous three trading sessions, shares
of Amedisys declined 0.35%, compared to the Nasdaq Composite Index, which
declined 1.62% during the same period. The Full Research Report on Amedisys
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/56b5_AMED

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)